Invenra Inc. announced a strategic collaboration with Catalent. The collaboration will harness the combined expertise and proprietary technologies of Invenra and Catalent to co-d discover novel bispecific antibody-drug conjugates. Both companies share a commitment to developing novel therapeutic solutions with the potential to make a meaningful impact in the lives of patients.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
56.53 USD | +0.28% | +1.22% | +25.82% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+25.82% | 10.23B | |
+33.43% | 700B | |
+27.63% | 569B | |
-5.12% | 358B | |
+19.59% | 330B | |
+4.89% | 287B | |
+15.74% | 236B | |
+6.45% | 202B | |
-8.83% | 197B | |
+4.26% | 161B |
- Stock Market
- Equities
- CTLT Stock
- News Catalent, Inc.
- Invenra Inc. Announces Strategic Collaboration with Catalent to Co-Discover Novel Bispecific ADCs